MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
About MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
5
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
1
Pfizer
1
Queen Mary University of London
1
Clinical Trials at MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
During the past decade, MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on
average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
2007-08-30
2016-05-31
Completed
3,942
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
2014-01-01
2020-07-31
Unknown status
333
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
2015-04-17
2021-03-24
Completed
609
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
2017-12-28
2019-01-28
Terminated
22
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
2019-01-24
2024-06-01
Active, not recruiting
430
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
2018-05-30
2023-05-30
Active, not recruiting
359
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
2020-10-13
2028-04-03
Recruiting
1,900
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken"
#1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Trium Analysis Online GmbH" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
According to Clinical.Site data, the most researched conditions in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are
"Breast Cancer" (2 trials), "Colorectal Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Estrogen Receptor Positive Breast Cancer" (1 trials) and "Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" in a lesser frequency.
Clinical Trials Intervention Types at MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
Most popular intervention types in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are "Drug" (8 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (3 trials), "Pertuzumab" (2 trials), "Trastuzumab" (2 trials), "5-FU/LV" (1 trials) and "5-Fluorouracil" (1 trials). Other intervention names were less common.
Clinical Trials Genders at MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
The vast majority of trials in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken" are
7 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
Currently, there are NaN active trials in "MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".